Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C

New England Journal of Medicine

Volumn 339, Issue 21, 1998, Pages 1493-1499

  Davis, Gary L ^a   Esteban Mur, Rafael ^b   Rustgi, Vinod ^c   Hoefs, John ^d   Gordon, Stuart C ^e   Trepo, Christian ^f   Shiffman, Mitchell L ^g   Zeuzem, Stefan ^h   Craxi, Antonio ⁱ   Ling, Mei Hsiu ^j   Albrecht, Janice ^j  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Inova Inst of Res and Education   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f HÔTEL DIEU   (France)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ROBETRON; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 0032547944     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199811193392102     Document Type: Article

References (45)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:Suppl 1: 62S-65S.
2. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327: 1906-11.
3. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B posttransfusion hepatitis: looking back in the second decade. Ann Intern Med 1993;119:110-5.
4. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-8.
5. Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2:219-28.
6. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
7. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
8. Tiné F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-9.
9. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
10. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62. [Erratum, N Engl J Med 1996;334:1143.]
11. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial. J Hepatol 1995;23:487-96.
12. Shiffman ML, Hoffman CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996;24:21-6.
13. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26:Suppl 1:83S-88S.
14. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1132-46.
15. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
16. Di Bisceglie AM, Shindo M, Fong T-L, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
17. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7.
18. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7
19. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23:Suppl 2: 8-12.
20. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-7.
21. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
22. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997;26: Suppl 1:137S-142S.
23. Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J Infect Dis 1993;167:780-1.
24. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31: 103-15.
25. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:Suppl 1:122S-127S.
26. Davis GL, Lau JYN, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-41.
27. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
28. Lindsay KL. Therapy of chronic hepatitis C: overview. Hepatology 1997;26:Suppl 1:71S-77S.
29. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
30. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
31. Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley, 1986.
32. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4. [Erratum, Lancet 1993;342:504.]
33. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
34. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
35. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26:Suppl 1:112S-121S.
36. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy. Ann Intern Med 1995;122:586-91.
37. Picciotti A, Brizzolara R, Campo N, et al. Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis C. Hepatology 1996:24:Suppl:273A. abstract.
38. Le X, Zhou X, Dai X. Evaluation of interferon-α-2b for the treatment of relapsed hepatitis-C. Hepatology 1996;24:Suppl:536A. abstract.
39. Fuschi P, Almasio P, Di Marco V, et al. Should patients with chronic hepatitis C who relapse after interferon (IFN) be retreated? J Hepatol 1997;26:Suppl 1:192. abstract.
40. Keeffe EB, Hollinger FB, Consensus Interferon Study Group. Therapy of hepatitis C: consensus interferon trials. Hepatology 1997;26:Suppl 1: 101S-107S.
41. Toyoda H, Nakano S, Takeda I, et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994;89:1453-7.
42. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon alfa-2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C: a controlled randomized trial. Dig Dis Sci 1996; 41:149-54.
43. Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997;35:187-92.
44. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-22.
45. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26:Suppl 1:2S-10S.